Day: December 8, 2020

Tikun Olam is Israel’s premier medical cannabis company with over 10 years of on-the-ground and clinical data depicting how its unique genetics affected medical patients with specific conditions including Crohn’s Disease, Epilepsy, PTSD, MS, and chronic painMariMed’s licensed subsidiary ARL Healthcare cultivates Tikun cannabis and will distribute its products at its Panacea Wellness Dispensary and to other select Massachusetts dispensariesNORWOOD, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) — International cannabis pioneer Tikun Olam’s award-winning heirloom cannabis products will be available for purchase in Massachusetts this week. MariMed, Inc. (MRMD:OTCQX) (the “Company” or “MariMed”), which has exclusive rights to grow, process, and market Tikun branded products in Massachusetts, will mark this milestone expansion of its product...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, Dec. 08, 2020 (GLOBE NEWSWIRE) —  K2 Gold Corporation (“K2” or the “Company”) (TSXV: KTO; OTCQB: KTGDF; FRANKFURT: 23K) is pleased to announce that it has entered into an agreement with Haywood Securities Inc., on behalf of a syndicate of underwriters (collectively the “Underwriters”), pursuant to which the Underwriters have agreed to purchase on a bought deal private placement basis, 6,250,000 units (“Units”) at a price of C$0.56 per Unit (the “Offering Price”), for aggregate gross proceeds of C$3,500,000 (the “Offering”).Each Unit will consist of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”)....

CALGARY, Alberta, Dec. 08, 2020 (GLOBE NEWSWIRE) — Gibson Energy Inc. announced today that it has reached another milestone in its sustainability journey by being recognized by CDP (formerly Carbon Disclosure Project), a recognized leader in environmental reporting, by receiving an A- rating. CDP’s scoring methodology assesses companies on the comprehensiveness of their disclosure, awareness and management of environmental risks and demonstration of best practices associated with environmental leadership.“The focused work we are doing to further our ESG goals has been validated today and we are thrilled to receive this acknowledgement by CDP,” said Steve Spaulding, President and Chief Executive Officer. “During this unprecedented health and economic crisis, we remain committed to ensuring our actions position Gibson well for future...

SOUTH SAN FRANCISCO, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that it will wind-down its microbiome program, enabling the company to prioritize resources and focus on the advancement of its pipeline of novel core inhibitors for chronic HBV.“Upon thoughtful consideration of our corporate strategy and strengths, we have made the difficult decision to wind-down our microbiome program in order to fully dedicate our resources and focus toward delivering a new class of novel HBV therapies to patients,” said John McHutchison, AO, MD, Chief Executive Officer and President. “We deeply appreciate the invaluable contributions of the microbiome team, who played an important role...

Prospective Accretive Acquisition Expected to Add New Utilities, Telecom and Financial Institution Customers as Well as Proprietary Document Composition Technology, Including Electronic Bill Presentment, to Support Key Growth InitiativesSAN ANTONIO, Dec. 08, 2020 (GLOBE NEWSWIRE) — Usio, Inc. (Nasdaq: USIO), an integrated electronic payment solutions provider, today announced that it has entered into a non-binding Letter of Intent (LOI) to acquire the assets of Information Management Solutions, LLC (IMS). IMS is an established provider of electronic bill presentment, document composition, document decomposition and printing and mailing services serving hundreds of customers representing a wide range of industry verticals, including utilities and financial institutions.Kelly Dowe, Co-founder of IMS, commented, “IMS is very pleased...

NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by Delcath. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Delcath also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold in the public offering.Delcath intends to use the net proceeds from this offering for (i) the completion...

NEW YORK and VIENNA, Austria, Dec. 08, 2020 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it intends to offer and sell shares of its common stock and shares of Series A convertible preferred stock in an underwritten public offering (the “Offering”). HOOKIPA also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the Offering, including the shares of common stock underlying the Series A convertible preferred stock. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering. All of...

TUCSON, Ariz., Dec. 08, 2020 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has launched an Early Access Program for its whole transcriptome panel using the HTG EdgeSeq technology. The Early Access Program is intended to allow select customers access to the panel in their laboratories or through services to be performed in our development laboratory prior to commercial launch of this product.HTG announced the completion of proof of concept for a prototype whole transcriptome panel and demonstrated technical feasibility in November 2020. The panel is expected to allow for analysis of the entire known human transcriptome (approximately 20,000 mRNA targets) while retaining the advantages of HTG’s smaller targeted...